Almac Group is a pharmaceutical company focusing on contract development, manufacturing services, and integrated solutions for the biotech and pharma sectors. Founded in Northern Ireland, the company offers a wide range of services, including R&D;, biomarker discovery, API manufacture, formulation development, clinical trial supply, IXRS technology, commercial-scale manufacture, and companion diagnostic development. After more than 40 years of organic growth, Almac now employs more than 4,500 highly skilled personnel across operations in the U.K., Ireland, the U.S. (in Pennsylvania, North Carolina, and California), and Asia (in Singapore and Tokyo).
The company is known for its diverse workforce and strong employee retention, with staff members staying an average of 5.7 years. Almac Group generates annual revenue of $862.5 million and has established itself as a key player in the pharmaceutical industry. CEO Alan David Armstrong leads the company to continually invest in state-of-the-art services and cutting-edge technology to support clients across the entire biopharmaceutical product lifecycle.
